KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 99 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q1 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $787,956 | +23.4% | 45,363 | +0.0% | 0.02% | +41.7% |
| Q2 2023 | $638,683 | +34.4% | 45,361 | +2.7% | 0.01% | +33.3% |
| Q1 2023 | $475,087 | -26.5% | 44,153 | +2.3% | 0.01% | -30.8% |
| Q4 2022 | $646,417 | +16.7% | 43,152 | +0.0% | 0.01% | +18.2% |
| Q3 2022 | $554,000 | +43.2% | 43,141 | +8.3% | 0.01% | +57.1% |
| Q2 2022 | $387,000 | +4.9% | 39,832 | +7.6% | 0.01% | +16.7% |
| Q1 2022 | $369,000 | -12.1% | 37,015 | +3.9% | 0.01% | +20.0% |
| Q4 2021 | $420,000 | +2.7% | 35,614 | -0.6% | 0.01% | 0.0% |
| Q3 2021 | $409,000 | +96.6% | 35,814 | +141.8% | 0.01% | +150.0% |
| Q2 2021 | $208,000 | -24.4% | 14,812 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $275,000 | +3.8% | 14,812 | -0.7% | 0.00% | 0.0% |
| Q4 2020 | $265,000 | -72.8% | 14,912 | -76.5% | 0.00% | -75.0% |
| Q3 2020 | $974,000 | -56.4% | 63,512 | -27.5% | 0.01% | -53.8% |
| Q2 2020 | $2,233,000 | – | 87,607 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 2,374,392 | $36,376,000 | 4.43% |
| Opaleye Management Inc. | 338,000 | $8,778,000 | 1.72% |
| Lion Point Capital, LP | 495,748 | $7,594,000 | 1.67% |
| Fairmount Funds Management LLC | 212,746 | $3,259,000 | 1.38% |
| Vivo Capital, LLC | 1,151,622 | $17,643,000 | 1.02% |
| Spearhead Capital Advisors, LLC | 270,117 | $4,138,000 | 0.79% |
| Integral Health Asset Management, LLC | 120,000 | $1,838,000 | 0.56% |
| Endurant Capital Management LP | 117,480 | $1,800,000 | 0.53% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,990 | $3,983,000 | 0.39% |
| Ikarian Capital, LLC | 342,998 | $5,254,000 | 0.38% |